Tebentafusp induces systemic immune activation, but tumor immune remodeling remains incompletely validated: a narrative review in metastatic uveal melanoma
4 affiliations
- 1Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
- 2Department of Oncology, Comprehensive Cancer Center, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
- 3Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
- 4Melanoma Medical Oncology Unit, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Abstract
Background: Tebentafusp improves survival in HLA-A*02:01-positive metastatic uveal melanoma, yet the human evidence linking early systemic immune activation to remodeling of metastatic tumors is dispersed across overlapping translational reports.
Methods: We performed a PRISMA-style, search-informed narrative review and descriptive evidence mapping of human reports evaluating baseline or on-treatment immune measurements in tebentafusp-treated uveal melanoma. PubMed/MEDLINE, Embase, and CENTRAL were searched for reports published from January 2015 to 9 December 2025, with an updated search on 9 June 2026. Reports were linked to their underlying trial or cohort before synthesis.
Results: Overall, 286 records were screened, 21 full-text reports or complete abstracts were assessed, and 10 reports were retained. These represented three principal evidence units rather than 10 independent studies: NCT02570308, NCT03070392, and an independent serial skin-biopsy cohort. Blood-based analyses consistently showed early cytokine induction and transient lymphocyte changes after tebentafusp dosing. Paired metastatic-tissue analyses reported increased CD3 and CD8 cell density and interferon-response programs by day 16, but these observations derived predominantly from overlapping analyses of NCT02570308. Baseline and on-treatment immune features were associated with survival in exploratory analyses. Skin biopsies provided independent evidence of on-target cutaneous pharmacodynamics but only indirect evidence regarding metastatic tumor remodeling.
Conclusion: Tebentafusp is associated with consistently observed early systemic immune activation across overlapping analyses, but treatment-associated metastatic tumor immune remodeling remains incompletely validated. The available evidence supports temporal coherence rather than a proven causal systemic-to-tumor pathway. Future studies should use prospective paired blood and liver sampling, harmonized time points, prespecified immune endpoints, and mediation analyses linking immune changes to clinical outcomes.
Related
- Epigenome Alterations and 3D Chromatin Architecture Remodeling in Inflammatory Macrophage Activation under Diabetic Conditions
- Mast cell phenotypic remodeling toward a PD-1-positive, Chymase-negative phenotype is associated with metastatic melanoma and poor survival.
- Multi-omics profiling of the choroid plexus reveals developmental cellular remodeling, early immune gene activation, and epithelial cell heterogeneity
- Concentration-Associated DNA Methylation Remodeling of Oncogenic Signaling Networks Following Moringa oleifera Treatment in Metastatic PC3 Prostate Cancer Cells
- Bacterial toxin activation and deployment: Context-dependent links to host immune remodeling
BibTeX
@article{rifaldi2026tebentafusp,
title = {{Tebentafusp induces systemic immune activation, but tumor immune remodeling remains incompletely validated: a narrative review in metastatic uveal melanoma}},
author = {Francesca Rifaldi and Filippo De Braud and Michele Del Vecchio and Lorenza Di Guardo},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1934256},
url = {https://doi.org/10.3389/fimmu.2026.1934256},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tebentafusp induces systemic immune activation, but tumor immune remodeling remains incompletely validated: a narrative review in metastatic uveal melanoma
AU - Francesca Rifaldi
AU - Filippo De Braud
AU - Michele Del Vecchio
AU - Lorenza Di Guardo
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1934256
UR - https://doi.org/10.3389/fimmu.2026.1934256
AB - Background: Tebentafusp improves survival in HLA-A*02:01-positive metastatic uveal melanoma, yet the human evidence linking early systemic immune activation to remodeling of metastatic tumors is dispersed across overlapping translational reports. Methods: We performed a PRISMA-style, search-informed narrative review and descriptive evidence mapping of human reports evaluating baseline or on-treatment immune measurements in tebentafusp-treated uveal melanoma. PubMed/MEDLINE, Embase, and CENTRAL were searched for reports published from January 2015 to 9 December 2025, with an updated search on 9 June 2026. Reports were linked to their underlying trial or cohort before synthesis. Results: Overall, 286 records were screened, 21 full-text reports or complete abstracts were assessed, and 10 reports were retained. These represented three principal evidence units rather than 10 independent studies: NCT02570308, NCT03070392, and an independent serial skin-biopsy cohort. Blood-based analyses consistently showed early cytokine induction and transient lymphocyte changes after tebentafusp dosing. Paired metastatic-tissue analyses reported increased CD3 and CD8 cell density and interferon-response programs by day 16, but these observations derived predominantly from overlapping analyses of NCT02570308. Baseline and on-treatment immune features were associated with survival in exploratory analyses. Skin biopsies provided independent evidence of on-target cutaneous pharmacodynamics but only indirect evidence regarding metastatic tumor remodeling. Conclusion: Tebentafusp is associated with consistently observed early systemic immune activation across overlapping analyses, but treatment-associated metastatic tumor immune remodeling remains incompletely validated. The available evidence supports temporal coherence rather than a proven causal systemic-to-tumor pathway. Future studies should use prospective paired blood and liver sampling, harmonized time points, prespecified immune endpoints, and mediation analyses linking immune changes to clinical outcomes.
SN - 1664-3224
ER -